Piper Sandler analyst Matt O'Brien does not believe the medical device correction announced this morning will significantly impact revenue growth for Insulet this year or in the coming years. The issue that surfaced today is found in the company's Personal Diabetes Managers and not its Pod, which delivers the insulin and is the most critical component of the overall system, O'Brien tells investors in a research note. As such, the analyst continues to view the technology as highly efficacious and safe and he anticipates the clinical community will as well. O'Brien remains a buyer of Insulet with an Overweight rating